NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant development

EMBO Mol Med. 2021 Mar 5;13(3):e12834. doi: 10.15252/emmm.202012834. Epub 2021 Feb 8.

Abstract

Herein, we demonstrate that NFAT, a key regulator of the immune response, translocates from cytoplasm to nucleolus and interacts with NF45/NF90 complex to collaboratively promote rDNA transcription via triggering the directly binding of NF45/NF90 to the ARRE2-like sequences in rDNA promoter upon T-cell activation in vitro. The elevated pre-rRNA level of T cells is also observed in both mouse heart or skin transplantation models and in kidney transplanted patients. Importantly, T-cell activation can be significantly suppressed by inhibiting NF45/NF90-dependent rDNA transcription. Amazingly, CX5461, a rDNA transcription-specific inhibitor, outperformed FK506, the most commonly used immunosuppressant, both in terms of potency and off-target activity (i.e., toxicity), as demonstrated by a series of skin and heart allograft models. Collectively, this reveals NF45/NF90-mediated rDNA transcription as a novel signaling pathway essential for T-cell activation and as a new target for the development of safe and effective immunosuppressants.

Keywords: CX5461; NF45/NF90; NFAT; nucleolus; organ transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA, Ribosomal / genetics
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Mice
  • Nuclear Factor 45 Protein* / genetics
  • Nuclear Factor 45 Protein* / metabolism
  • Nuclear Factor 90 Proteins* / genetics
  • Nuclear Factor 90 Proteins* / metabolism
  • Promoter Regions, Genetic

Substances

  • DNA, Ribosomal
  • Immunosuppressive Agents
  • Nuclear Factor 45 Protein
  • Nuclear Factor 90 Proteins